Guardant360 / Guardant360 Liquid CDx
A widely used blood-based comprehensive genomic profiling platform for advanced solid tumors, including FDA-approved companion diagnostic use in selected cancers.
Booking + Second Opinion
Blood-Based Molecular Profiling
Liquid Biopsy ctDNA Test
Book a blood-based liquid biopsy for cancer mutation profiling and expert ctDNA report interpretation.
Liquid biopsy is a blood-based cancer genomic test that analyzes circulating tumor DNA (ctDNA) to identify actionable mutations, resistance markers, MSI/TMB signals, and targeted therapy options when tissue biopsy is difficult or when treatment response needs monitoring.
4.9/5 Patient Rating
Verified Specialists
Private & Confidential
Blood-Based Molecular Profiling
Liquid Biopsy ctDNA Test
Book a blood-based liquid biopsy for cancer mutation profiling and expert ctDNA report interpretation.
Liquid biopsy is a blood-based cancer genomic test that analyzes circulating tumor DNA (ctDNA) to identify actionable mutations, resistance markers, MSI/TMB signals, and targeted therapy options when tissue biopsy is difficult or when treatment response needs monitoring.
500+
Genes Analyzed
24hr
Expert Callback
95%
Clinical Actionability
4.9/5 Patient Rating
Verified Specialists
Private & Confidential
Understanding The Test
What is Liquid Biopsy?
Liquid biopsy is a blood-based genomic test for cancer. Instead of taking a fresh tumor tissue sample, the lab separates plasma from blood and analyzes circulating cell-free DNA, including circulating tumor DNA (ctDNA), to look for cancer-related mutations that may guide treatment.
It is especially useful when tumor tissue is unavailable, a repeat biopsy is risky, cancer has progressed on treatment, or the oncologist wants a faster molecular profile. A negative liquid biopsy does not always rule out mutations because some tumors shed very little ctDNA into blood, so tissue testing may still be needed when clinically feasible.
No surgical biopsy is needed for sample collection
Useful when tissue is insufficient, inaccessible, or too old for genomic testing
Can detect resistance mutations after targeted therapy stops working
Existing Guardant360, FoundationOne Liquid CDx, Tempus, Caris, or ctDNA reports can be reviewed without repeating the test
Quick Facts
Blood Draw
Sample Needed
7–14 Days
Report Time
Advanced Solid Tumors
Best Use
Molecular Oncology Team
Reviewed By
Cost Reference
Liquid Biopsy Test Cost in India
Transparent liquid biopsy pricing across India — final cost depends on platform, panel size, and whether report review is included.
Starting Prices
Compare Test Prices
Focused ctDNA Panelupto ₹45,000
Comprehensive Liquid Biopsyupto ₹90,000
Existing Report Reviewupto ₹7,500
Indicative starting prices for common genomics test options.
What's Included
Focused ctDNA Panel
Targeted panel for common driver and resistance mutations
upto ₹45,000
Blood sample collection
Common solid tumor driver genes
Resistance mutation review
7–10 day expected turnaround
Liquid biopsy test cost in India varies by platform and clinical objective. If tissue biopsy is feasible and a plasma result is negative, your oncologist may still recommend tissue testing.
Second Opinion Service
Second Opinion on Your Liquid Biopsy Report
If you already have a Guardant360, FoundationOne Liquid CDx, Tempus, Caris, or hospital ctDNA report, our molecular oncology team can review it and explain whether the findings support targeted therapy, immunotherapy, repeat tissue biopsy, or tumor board discussion.
What our experts review
ctDNA Report Interpretation
We explain actionable mutations, ctDNA fraction, MSI/TMB, resistance markers, and VUS findings in clear treatment-focused language.
Platform-Specific Review
We check panel scope, detected alterations, companion diagnostic claims, clinical significance tiers, and limitations for the exact report you received.
Targeted Therapy Matching
Detected alterations are mapped to approved targeted therapies, off-label evidence, and options available in India.
Negative Report Next Steps
If no mutation was detected, we review ctDNA fraction and clinical context to decide whether tissue testing, repeat testing, or monitoring is needed.
Resistance Mutation Review
We interpret progression-related findings after EGFR, ALK, endocrine therapy, HER2 therapy, or other targeted treatments.
Clinical Trial Eligibility
We identify whether your liquid biopsy findings may open mutation-matched trial options or tumor board recommendations.
Why patients trust us
- Reviewed by certified molecular oncologists
- Response within 2 business hours
- 100% confidential — your data stays private
Not sure what your Liquid Biopsy report means?
Guardant360, FoundationOne & More
Popular Liquid Biopsy Tests We Can Help You Book or Review
Different liquid biopsy platforms use different panel sizes, reporting formats, and companion diagnostic claims. Our major value is helping you choose the right test, or interpret a report you already have.
FoundationOne Liquid CDx
A plasma cfDNA test covering 300+ genes, with reporting for selected therapy-linked biomarkers and clinical trial options.
Report Review
Tempus xF / xF+
Liquid biopsy panels ranging from focused ctDNA profiling to broader 500+ gene testing for drivers and resistance alterations.
Treatment Matching
Caris Assure
A whole-blood liquid biopsy approach designed to separate tumor findings from non-tumor signals such as clonal hematopoiesis.
Complex Reports
Standard ctDNA Panel
Targeted blood-based panels for common driver genes when fast mutation profiling is needed and broad testing is not required.
Focused Testing
Already have a Guardant360 or other liquid biopsy report?
Our molecular oncologists review reports from any platform and explain what your mutations, ctDNA fraction, MSI/TMB, resistance markers, and VUS findings mean for the next treatment decision — no re-testing needed unless clinically necessary.
Understanding Your Report
What Will Your Liquid Biopsy Report Say?
Most ctDNA reports group findings into clinically actionable alterations, resistance signals, biomarker scores, ctDNA fraction, and variants that need expert interpretation.
Actionable Mutations
Mutations matched to targeted therapy options, such as EGFR, ALK, KRAS G12C, BRAF, HER2, MET, RET, ROS1, NTRK, BRCA1/2, or PIK3CA.
MSI Status
Some panels report microsatellite instability, which may support immunotherapy eligibility when interpreted with cancer type and treatment history.
TMB Score
Blood tumor mutational burden may be reported by selected platforms and can contribute to immunotherapy discussions in appropriate cancers.
ctDNA Fraction
The percentage or level of tumor DNA detected in blood. Low ctDNA can make a negative report less conclusive.
Resistance Mutations
Findings such as EGFR T790M/C797S, ESR1, MET amplification, or other escape mechanisms may explain progression on current therapy.
VUS
Variants of Unknown Significance are not actionable today but may be tracked over time as evidence changes.
Already have a liquid biopsy report?
Get a second opinion to understand what your report actually says for treatment: which mutations matter, which findings are uncertain, and whether tissue testing or a tumor board review should come next.
Related Tests
Other Genomic Tests You May Need
NGS Testing
Comprehensive genomic profiling for cancer treatment planning
Tumor DNA Sequencing
Tissue-based somatic profiling for targeted therapy
Hereditary Cancer Panel
Inherited cancer risk testing for patients and families
Not sure which test applies to you?
Get a second opinion or consult our multidisciplinary tumor board to confirm the right genomic test for your diagnosis.
Cancers Covered
Liquid Biopsy Applies Across Cancer Types
Lung Cancer
Liquid biopsy is commonly used to detect EGFR, ALK, ROS1, RET, MET, BRAF, HER2, KRAS G12C, and resistance markers in advanced NSCLC.
Breast Cancer
ctDNA testing may identify ESR1, PIK3CA, HER2, BRCA1/2, and resistance-related alterations that can affect later-line treatment choices.
Colon Cancer
Liquid biopsy can help review RAS/BRAF status, HER2 amplification, MSI signals, and resistance patterns when tissue is limited.
Prostate Cancer
ctDNA panels may detect BRCA1/2, ATM, CDK12, MSI/TMB, and other DNA repair alterations relevant to PARP inhibitors or trials.
Ovarian Cancer
Liquid biopsy may help assess BRCA/HRR alterations and evolving resistance when repeat tissue sampling is difficult.
Pancreatic Cancer
ctDNA testing can look for KRAS, BRCA1/2, PALB2, MSI-H, NTRK, and other uncommon but important therapy-linked findings.
Common Questions
Frequently Asked Questions
Answers for both first-time patients and those who already have a Liquid Biopsy report in hand.
What is a liquid biopsy test for cancer?
A liquid biopsy is a blood-based cancer genomic test that analyzes circulating tumor DNA (ctDNA) in plasma. It can identify actionable mutations, resistance markers, and selected biomarkers that may help guide targeted therapy, immunotherapy discussions, clinical trial matching, or the need for tissue testing.
How is liquid biopsy different from tissue biopsy?
Tissue biopsy tests DNA directly from tumor tissue, while liquid biopsy tests tumor DNA fragments circulating in blood. Liquid biopsy is less invasive and useful when tissue is unavailable or repeat biopsy is risky, but a negative plasma result does not always rule out tumor mutations because some cancers shed very little ctDNA.
Who should consider liquid biopsy?
Liquid biopsy is commonly considered for advanced or metastatic solid tumors, patients who cannot undergo repeat tissue biopsy, cases where tissue is insufficient for NGS, cancer progression after targeted therapy, or when a fast blood-based mutation profile is clinically useful.
What mutations can liquid biopsy detect?
Depending on the panel, liquid biopsy can detect alterations in genes such as EGFR, ALK, KRAS, BRAF, HER2/ERBB2, MET, RET, ROS1, NTRK, PIK3CA, ESR1, BRCA1/2, and others. Some platforms also report copy number changes, fusions, MSI-H, blood TMB, ctDNA fraction, and resistance mutations.
What is the cost of liquid biopsy test in India?
Liquid biopsy test cost in India usually varies by panel size and platform. Focused ctDNA panels may cost less than broad platforms such as Guardant360, FoundationOne Liquid CDx, Tempus xF/xF+, or Caris Assure. BigOHealth can help compare options and provide current pricing based on your cancer type and treatment question.
How long does a ctDNA liquid biopsy report take?
Most liquid biopsy reports are available in 7–14 business days after sample collection and lab receipt. Turnaround can vary by platform, logistics, panel complexity, and whether expert report interpretation is added.
Can you review my Guardant360 or FoundationOne Liquid CDx report?
Yes. BigOHealth can review existing Guardant360, FoundationOne Liquid CDx, Tempus, Caris, or hospital ctDNA reports. Our molecular oncology team explains actionable findings, resistance mutations, ctDNA fraction, MSI/TMB, VUS, therapy relevance, and whether any repeat or tissue testing is needed.
Does a negative liquid biopsy mean there are no mutations?
No. A negative liquid biopsy can happen when the tumor is not shedding enough ctDNA into blood or when the mutation is outside the panel scope. If suspicion remains high and tissue biopsy is feasible, your oncologist may recommend tissue-based NGS or repeat testing.
Is liquid biopsy useful for lung cancer?
Yes. Liquid biopsy is especially useful in advanced lung cancer for detecting EGFR mutations, EGFR T790M/C797S resistance, ALK, ROS1, RET, MET exon 14, BRAF, HER2, KRAS G12C, and other findings that may guide targeted therapy decisions.
Can liquid biopsy replace tissue biopsy?
Sometimes it can answer the treatment question without a new tissue procedure, especially when a positive actionable mutation is detected. But it does not fully replace tissue biopsy in all cases because tissue confirms diagnosis, histology, and may detect alterations missed in low-shedding plasma samples.
Still have questions about your Liquid Biopsy report or results?
